Viral vectors as vaccine carriers

Current Opinion in Virology

Volumn 21, Issue , 2016, Pages 1-8

  Ertl, Hildegund Cj ^a  

^a WISTAR INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NEUTRALIZING ANTIBODY; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; PARVOVIRUS VECTOR; SUBUNIT VACCINE; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 9; VIRUS VACCINE; VIRUS VECTOR; DRUG CARRIER; RECOMBINANT VACCINE;

ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; IMMUNE RESPONSE; IMMUNOGENICITY; INNATE IMMUNITY; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; ADAPTIVE IMMUNITY; ADENOVIRIDAE; ANIMAL; CLINICAL TRIAL (TOPIC); DEPENDOPARVOVIRUS; GENE VECTOR; GENETICS; HUMAN; IMMUNOLOGY; T LYMPHOCYTE;

ADAPTIVE IMMUNITY; ADENOVIRIDAE; ANIMALS; B-LYMPHOCYTES; CLINICAL TRIALS AS TOPIC; DEPENDOVIRUS; DRUG CARRIERS; GENETIC VECTORS; HUMANS; T-LYMPHOCYTES; VACCINES, SYNTHETIC;

EID: 84975032484     PISSN: 18796257     EISSN: 18796265     Source Type: Journal    
DOI: 10.1016/j.coviro.2016.06.001     Document Type: Review

References (115)

1. B. Moss, G.L. Smith, and M. Mackett Use of vaccinia virus as an infectious molecular cloning and expression vector Gene Amplif Anal 3 1983 201 213
2. E-J. Im, and T. Hanke MVA as a vector for vaccines against HIV-1 Expert Rev Vaccines 3 2004 S89 S97
3. S.J. Draper, M.G. Cottingham, and S.C. Gilbert Utilizing poxviral vectored vaccines for antibody induction-progress and prospects Vaccine 31 2013 4223 4230
4. C.J. Russell, and J.L. Hurwitz Sendai virus as a backbone for vaccines against RSV and other human paramyxoviruses Expert Rev Vaccines 15 2016 189 200
5. D. Kurup, C. Wirblich, H. Feldmann, A. Marzi, and M.J. Schnell Rhabdovirus-based vaccine platforms against henipaviruses J Virol 89 2015 144 154
6. A.B. Ryder, R. Nachbagauer, L. Buonocore, P. Palese, F. Krammer, and J.K. Rose Vaccination with vesicular stomatitis virus-vectored chimeric hemagglutinins protects mice against divergent influenza virus challenge strains J Virol 90 2015 2544 2550
7. Y.-N. Lee, H.S. Hwang, M.-C. Kim, Y.-T. Lee, Y.-J. Kim, F.E.-H. Lee, and S.-M. Kang Protection against respiratory syncytial virus by inactivated influenza virus carrying a fusion protein neutralizing epitope in a chimeric hemagglutinin Nanomedicine Nanotechnol Biol Med 12 2016 759 770
8. T.P. Monath, S.J. Seligman, J.S. Robertson, B. Guy, E.B. Hayes, R.C. Condit, J.L. Excler, L.M. Mac, B. Carbery, R.T. Chen, and et al. Live virus vaccines based on a yellow fever vaccine backbone: standardized template with key considerations for a risk/benefit assessment Vaccine 33 2015 62 72
9. A. Higuchi, H. Toriniwa, T. Komiya, and T. Nakayama Recombinant measles AIK-C vaccine strain expressing the prM-E antigen of Japanese Encephalitis Virus PLoS One 11 2016 e0150213
10. S. Ring, and L. Flatz Generation of lymphocytic choriomeningitis virus based vaccine vectors Methods Mol Biol Clifton NJ 1404 2016 351 364
11. F.L. Graham, and L. Prevec Adenovirus-based expression vectors and recombinant vaccines Biotechnol Read Mass 20 1992 363 390
12. Z.Q. Xiang, Y. Yang, J.M. Wilson, and H.C. Ertl E. Norrby, F. Brown, R. Chancock, H. Ginsberg, Rabies vaccines based on E1 deleted recombinant adenovirus In Vaccine 96 1996 Cold Spring Harbor Laboratory Press 189 193
13. F. Lemiale, H. Haddada, G.J. Nabel, D.E. Brough, C.R. King, and J.G.D. Gall Novel adenovirus vaccine vectors based on the enteric-tropic serotype 41 Vaccine 25 2007 2074 2084
14. D.H. Barouch, and L.J. Picker Novel vaccine vectors for HIV-1 Nat Rev Microbiol 12 2014 765 771
15. E. Barnes, A. Folgori, S. Capone, L. Swadling, S. Aston, A. Kurioka, J. Meyer, R. Huddart, K. Smith, R. Townsend, and et al. Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man Sci Transl Med 4 2012 115ra1
16. S. Afkhami, Y. Yao, and Z. Xing Methods and clinical development of adenovirus-vectored vaccines against mucosal pathogens Mol Ther Methods Clin Dev 3 2016 16030
17. F. Zhu, T. Chen, Y. Zhang, H. Sun, H. Cao, J. Lu, L. Zhao, and G. Li A novel adeno-associated virus-based genetic vaccine encoding the Hepatitis C Virus NS3/4 protein exhibits immunogenic properties in mice superior to those of an NS3-protein-based vaccine PLoS One 10 2015 e0142349
18. A. Ploquin, J. Szécsi, C. Mathieu, V. Guillaume, V. Barateau, K.C. Ong, K.T. Wong, F-L. Cosset, B. Horvat, and A. Salvetti Protection against henipavirus infection by use of recombinant adeno-associated virus-vector vaccines J Infect Dis 207 2013 469 478
19. X. Li, H. Cao, Q. Wang, B. Di, M. Wang, J. Lu, L. Pan, L. Yang, M. Mei, X. Pan, and et al. Novel AAV-based genetic vaccines encoding truncated dengue virus envelope proteins elicit humoral immune responses in mice Microbes Infect Inst Pasteur 14 2012 1000 1007
20. K. Nieto, C. Stahl-Hennig, B. Leuchs, M. Müller, L. Gissmann, and J.A. Kleinschmidt Intranasal vaccination with AAV5 and 9 vectors against human papillomavirus type 16 in rhesus macaques Hum Gene Ther 23 2012 733 741
21. G.J. Logan, L. Wang, M. Zheng, S.C. Cunningham, R.L. Coppel, and I.E. Alexander AAV vectors encoding malarial antigens stimulate antigen-specific immunity but do not protect from parasite infection Vaccine 25 2007 1014 1022
22. S.G. Hansen, J.B. Sacha, C.M. Hughes, J.C. Ford, B.J. Burwitz, I. Scholz, R.M. Gilbride, M.S. Lewis, A.N. Gilliam, A.B. Ventura, and et al. Cytomegalovirus vectors violate CD8+ T cell epitope recognition paradigms Science 340 2013 1237874
23. S.A. Vaidya, and G. Cheng Toll-like receptors and innate antiviral responses Curr Opin Immunol 15 2003 402 407
24. C. Lupfer, A. Malik, and T.-D. Kanneganti Inflammasome control of viral infection Curr Opin Virol 12 2015 38 46
25. L. Unterholzner The interferon response to intracellular DNA: why so many receptors? Immunobiology 218 2013 1312 1321
26. M. Dalod, R. Chelbi, B. Malissen, and T. Lawrence Dendritic cell maturation: functional specialization through signaling specificity and transcriptional programming EMBO J 33 2014 1104 1116
27. S.J. van Vliet, J. den Dunnen, S.I. Gringhuis, T.B. Geijtenbeek, and Y. van Kooyk Innate signaling and regulation of Dendritic cell immunity Curr Opin Immunol 19 2007 435 440
28. M.J. Benson, L.D. Erickson, M.W. Gleeson, and R.J. Noelle Affinity of antigen encounter and other early B-cell signals determine B-cell fate Curr Opin Immunol 19 2007 275 280
29. K. Igarashi, K. Ochiai, and A. Muto Architecture and dynamics of the transcription factor network that regulates B-to-plasma cell differentiation J Biochem (Tokyo) 141 2007 783 789
30. Y. Zhang, L. Garcia-Ibanez, and K.-M. Toellner Regulation of germinal center B-cell differentiation Immunol Rev 270 2016 8 19
31. K-P. Nera, M.K. Kyläniemi, and O. Lassila Regulation of B cell to plasma cell transition within the follicular B cell response Scand J Immunol 82 2015 225 234
32. D.F. Tough, and J. Sprent Lifespan of lymphocytes Immunol Res 14 1995 1 12
33. R. Elgueta, V.C. de Vries, and R.J. Noelle The immortality of humoral immunity Immunol Rev 236 2010 139 150
34. A.J. Sant Endogenous antigen presentation by MHC class II molecules Immunol Res 13 1994 253 267
35. E. Gutiérrez-Martínez, R. Planès, G. Anselmi, M. Reynolds, S. Menezes, A.C. Adiko, L. Saveanu, and P. Guermonprez Cross-presentation of cell-associated antigens by MHC Class I in dendritic cell subsets Front Immunol 6 2015 363
36. + T-cell help Eur J Immunol 42 2012 1080 1088
37. K.H.G. Mills Regulatory T cells: friend or foe in immunity to infection? Nat Rev Immunol 4 2004 841 855
38. S.M. Kaech, E.J. Wherry, and R. Ahmed Effector and memory T-cell differentiation: implications for vaccine development Nat Rev Immunol 2 2002 251 262
39. J.R. Vasconcelos, M.R. Dominguez, A.F. Araújo, J. Ersching, C.A. Tararam, O. Bruna-Romero, and M.M. Rodrigues Relevance of long-lived CD8(+) T effector memory cells for protective immunity elicited by heterologous prime-boost vaccination Front Immunol 3 2012 358
40. J. Sprent, and C.D. Surh Generation and maintenance of memory T cells Curr Opin Immunol 13 2001 248 254
41. R. Ahmed, and R.S. Akondy Insights into human CD8(+) T-cell memory using the yellow fever and smallpox vaccines Immunol Cell Biol 89 2011 340 345
42. B. Ye, X. Liu, X. Li, H. Kong, L. Tian, and Y. Chen T-cell exhaustion in chronic hepatitis B infection: current knowledge and clinical significance Cell Death Dis 6 2015 e1694
43. T. Watanabe, A. Bertoletti, and T.A. Tanoto PD-1/PD-L1 pathway and T-cell exhaustion in chronic hepatitis virus infection J Viral Hepatol 17 2010 453 458
44. H.T. Maecker, and V.C. Maino Analyzing T-cell responses to cytomegalovirus by cytokine flow cytometry Hum Immunol 65 2004 493 499
45. H. Li, M.O. Lasaro, B. Jia, S.W. Lin, L.H. Haut, K.A. High, and H.C.J. Ertl Capsid-specific T-cell responses to natural infections with adeno-associated viruses in humans differ from those of nonhuman primates Mol Ther J Am Soc Gene Ther 19 2011 2021 2030
46. A.D. Hislop, and G.S. Taylor T-Cell responses to EBV Curr Top Microbiol Immunol 391 2015 325 353
47. A.S. Tarun, R.F. Dumpit, N. Camargo, M. Labaied, P. Liu, A. Takagi, R. Wang, and S.H.I. Kappe Protracted sterile protection with Plasmodium yoelii pre-erythrocytic genetically attenuated parasite malaria vaccines is independent of significant liver-stage persistence and is mediated by CD8+ T cells J Infect Dis 196 2007 608 616
48. S.G. Hansen, J.C. Ford, M.S. Lewis, A.B. Ventura, C.M. Hughes, L. Coyne-Johnson, N. Whizin, K. Oswald, R. Shoemaker, T. Swanson, and et al. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine Nature 473 2011 523 527
49. M.C. Jung, H.M. Diepolder, and G.R. Pape T cell recognition of hepatitis B and C viral antigens Eur J Clin Invest 24 1994 641 650
50. U. Koszinowski, and H. Ertl Role of early viral surface antigens in cellular immune response to vaccinia virus Eur J Immunol 6 1976 679 683
51. M.I. Salazar, O. López-Ortega, G. León-Avila, J.E. Ramírez-Gónzalez, and M.E. Castro-Mussot The origin of the genetic variability of influenza viruses Gac. Médica México 146 2010 199 206
52. A.J. Brown Sequence variability in human immunodeficiency viruses: pattern and process in viral evolution AIDS Lond Engl 5 Suppl 2 1991 S35 S42
53. J.W. Yewdell Designing CD8+ T cell vaccines: it's not rocket science (yet) Curr Opin Immunol 22 2010 402 410
54. S.A. Prasad, C.C. Norbury, W. Chen, J.R. Bennink, and J.W. Yewdell Cutting edge: recombinant adenoviruses induce CD8 T cell responses to an inserted protein whose expression is limited to nonimmune cells J Immunol Baltim Md 1950 166 2001 4809 4812
55. A.T. Martino, S. Nayak, B.E. Hoffman, M. Cooper, G. Liao, D.M. Markusic, B.J. Byrne, C. Terhorst, and R.W. Herzog Tolerance induction to cytoplasmic beta-galactosidase by hepatic AAV gene transfer: implications for antigen presentation and immunotoxicity PLoS One 4 2009 e6376
56. Z. Xiang, Y. Li, A. Cun, W. Yang, S. Ellenberg, W.M. Switzer, M.L. Kalish, and H.C.J. Ertl Chimpanzee adenovirus antibodies in humans, sub-Saharan Africa Emerg Infect Dis 12 2006 1596 1599
57. S.L. Ludwig, J.F. Brundage, P.W. Kelley, R. Nang, C. Towle, D.P. Schnurr, L. Crawford-Miksza, and J.C. Gaydos Prevalence of antibodies to adenovirus serotypes 4 and 7 among unimmunized US Army trainees: results of a retrospective nationwide seroprevalence survey J Infect Dis 178 1998 1776 1778
58. A.R. Thorner, R. Vogels, J. Kaspers, G.J. Weverling, L. Holterman, A.A.C. Lemckert, A. Dilraj, L.M. McNally, P.M. Jeena, S. Jepsen, and et al. Age dependence of adenovirus-specific neutralizing antibody titers in individuals from sub-Saharan Africa J Clin Microbiol 44 2006 3781 3783
59. S. Boutin, V. Monteilhet, P. Veron, C. Leborgne, O. Benveniste, M.F. Montus, and C. Masurier Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors Hum Gene Ther 21 2010 704 712
60. R. Calcedo, L.H. Vandenberghe, G. Gao, J. Lin, and J.M. Wilson Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses J Infect Dis 199 2009 381 390
61. G. Cichon, S. Boeckh-Herwig, H.H. Schmidt, E. Wehnes, T. Müller, P. Pring-Akerblom, and R. Burger Complement activation by recombinant adenoviruses Gene Ther 8 2001 1794 1800
62. S.P. Buchbinder, D.V. Mehrotra, A. Duerr, D.W. Fitzgerald, R. Mogg, D. Li, P.B. Gilbert, J.R. Lama, M. Marmor, C. Del Rio, and et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial Lancet Lond Engl 372 2008 1881 1893
63. N. Tatsis, L. Tesema, E.R. Robinson, W. Giles-Davis, K. McCoy, G.P. Gao, J.M. Wilson, and H.C.J. Ertl Chimpanzee-origin adenovirus vectors as vaccine carriers Gene Ther 13 2006 421 429
64. S. Capone, A.M. D'Alise, V. Ammendola, S. Colloca, R. Cortese, A. Nicosia, and A. Folgori Development of chimpanzee adenoviruses as vaccine vectors: challenges and successes emerging from clinical trials Expert Rev Vaccines 12 2013 379 393
65. M. Duncan, M.R. Cranfield, H. Torano, H.M. Kuete, G.P. Lee, A. Glenn, J.T. Bruder, D. Rangel, D.E. Brough, and J.G. Gall Adenoviruses isolated from wild gorillas are closely related to human species C viruses Virology 444 2013 119 123
66. J. Lin, R. Calcedo, L.H. Vandenberghe, P. Bell, S. Somanathan, and J.M. Wilson A new genetic vaccine platform based on an adeno-associated virus isolated from a rhesus macaque J Virol 83 2009 12738 12750
67. N.A. Hutnick, D. Carnathan, K. Demers, G. Makedonas, H.C.J. Ertl, and M.R. Betts Adenovirus-specific human T cells are pervasive, polyfunctional, and cross-reactive Vaccine 28 2010 1932 1941
68. F. Mingozzi, M.V. Maus, D.J. Hui, D.E. Sabatino, S.L. Murphy, J.E.J. Rasko, M.V. Ragni, C.S. Manno, J. Sommer, H. Jiang, and et al. CD8(+) T-cell responses to adeno-associated virus capsid in humans Nat Med 13 2007 419 422
69. J.C. Fitzgerald, G-P. Gao, A. Reyes-Sandoval, G.N. Pavlakis, Z.Q. Xiang, A.P. Wlazlo, W. Giles-Davis, J.M. Wilson, and H.C.J. Ertl A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag J Immunol Baltim Md 1950 170 2003 1416 1422
70. P.W. Roelvink, A. Lizonova, J.G. Lee, Y. Li, J.M. Bergelson, R.W. Finberg, D.E. Brough, I. Kovesdi, and T.J. Wickham The coxsackievirus-adenovirus receptor protein can function as a cellular attachment protein for adenovirus serotypes from subgroups A, C, D, E, and F J Virol 72 1998 7909 7915
71. P. Mathias, T. Wickham, M. Moore, and G. Nemerow Multiple adenovirus serotypes use alpha v integrins for infection J Virol 68 1994 6811 6814
72. D. Sirena, B. Lilienfeld, M. Eisenhut, S. Kälin, K. Boucke, R.R. Beerli, L. Vogt, C. Ruedl, M.F. Bachmann, U.F. Greber, and et al. The human membrane cofactor CD46 is a receptor for species B adenovirus serotype 3 J Virol 78 2004 4454 4462
73. A. Gaggar, D.M. Shayakhmetov, and A. Lieber CD46 is a cellular receptor for group B adenoviruses Nat Med 9 2003 1408 1412
74. E.-J. Hayton, A. Rose, U. Ibrahimsa, M. Del Sorbo, S. Capone, A. Crook, A.P. Black, L. Dorrell, and T. Hanke Safety and tolerability of conserved region vaccines vectored by plasmid DNA, simian adenovirus and modified vaccinia virus ankara administered to human immunodeficiency virus type 1-uninfected adults in a randomized, single-blind phase I trial PLoS One 9 2014 e101591
75. S. Yuen, J. Smith, L. Caruso, M. Balan, and M.A. Opavsky The coxsackie-adenovirus receptor induces an inflammatory cardiomyopathy independent of viral infection J Mol Cell Cardiol 50 2011 826 840
76. B. Thaci, I.V. Ulasov, D.A. Wainwright, and M.S. Lesniak The challenge for gene therapy: innate immune response to adenoviruses Oncotarget 2 2011 113 121
77. D.M. Appledorn, S. Patial, A. McBride, S. Godbehere, N. Van Rooijen, N. Parameswaran, and A. Amalfitano Adenovirus vector-induced innate inflammatory mediators, MAPK signaling, as well as adaptive immune responses are dependent upon both TLR2 and TLR9 in vivo J Immunol Baltim Md 1950 181 2008 2134 2144
78. T. Yamaguchi, K. Kawabata, N. Koizumi, F. Sakurai, K. Nakashima, H. Sakurai, T. Sasaki, N. Okada, K. Yamanishi, and H. Mizuguchi Role of MyD88 and TLR9 in the innate immune response elicited by serotype 5 adenoviral vectors Hum Gene Ther 18 2007 753 762
79. D.R. Casimiro, L. Chen, T.-M. Fu, R.K. Evans, M.J. Caulfield, M.-E. Davies, A. Tang, M. Chen, L. Huang, V. Harris, and et al. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene J Virol 77 2003 6305 6313
80. D.G. Carnathan, K.S. Wetzel, J. Yu, S.T. Lee, B.A. Johnson, M. Paiardini, J. Yan, M.P. Morrow, N.Y. Sardesai, D.B. Weiner, and et al. Activated CD4 + CCR5+ T cells in the rectum predict increased SIV acquisition in SIVGag/Tat-vaccinated rhesus macaques Proc Natl Acad Sci U S A 112 2015 518 523
81. Z.Q. Xiang, L. Greenberg, H.C. Ertl, and C.E. Rupprecht Protection of non-human primates against rabies with an adenovirus recombinant vaccine Virology 450 2014 243 249
82. G. Jiang, M. Shi, S. Conteh, N. Richie, G. Banania, H. Geneshan, A. Valencia, P. Singh, J. Aguiar, K. Limbach, and et al. Sterile protection against Plasmodium knowlesi in rhesus monkeys from a malaria vaccine: comparison of heterologous prime boost strategies PLoS One 4 2009 e6559
83. S. Biswas, P. Choudhary, S.C. Elias, K. Miura, K.H. Milne, S.C. de Cassan, K.A. Collins, F.D. Halstead, C.M. Bliss, K.J. Ewer, and et al. Assessment of humoral immune responses to blood-stage malaria antigens following ChAd63-MVA immunization, controlled human malaria infection and natural exposure PLoS One 9 2014 e107903
84. A.J. Bett, S.A. Dubey, D.V. Mehrotra, L. Guan, R. Long, K. Anderson, K. Collins, C. Gaunt, R. Fernandez, S. Cole, and et al. Comparison of T cell immune responses induced by vectored HIV vaccines in non-human primates and humans Vaccine 28 2010 7881 7889
85. B. Barefoot, N.J. Thornburg, D.H. Barouch, J-S. Yu, C. Sample, R.E. Johnston, H.X. Liao, T.B. Kepler, B.F. Haynes, and E. Ramsburg Comparison of multiple vaccine vectors in a single heterologous prime-boost trial Vaccine 26 2008 6108 6118
86. S. Colloca, E. Barnes, A. Folgori, V. Ammendola, S. Capone, A. Cirillo, L. Siani, M. Naddeo, F. Grazioli, M.L. Esposito, and et al. Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species Sci Transl Med 4 2012 115ra2
87. H. Chen, Z.Q. Xiang, Y. Li, R.K. Kurupati, B. Jia, A. Bian, D.M. Zhou, N. Hutnick, S. Yuan, C. Gray, and et al. Adenovirus-based vaccines: comparison of vectors from three species of adenoviridae J Virol 84 2010 10522 10532
88. N. Tatsis, J.C. Fitzgerald, A. Reyes-Sandoval, K.C. Harris-McCoy, S.E. Hensley, D. Zhou, S-W. Lin, A. Bian, Z.Q. Xiang, A. Iparraguirre, and et al. Adenoviral vectors persist in vivo and maintain activated CD8+ T cells: implications for their use as vaccines Blood 110 2007 1916 1923
89. A. Reyes-Sandoval, J.C. Fitzgerald, R. Grant, S. Roy, Z.Q. Xiang, Y. Li, G.P. Gao, J.M. Wilson, and H.C.J. Ertl Human immunodeficiency virus type 1-specific immune responses in primates upon sequential immunization with adenoviral vaccine carriers of human and simian serotypes J Virol 78 2004 7392 7399
90. O. Nicholson, F. Dicandilo, J. Kublin, X. Sun, E. Quirk, M. Miller, G. Gray, J. Pape, M.N. Robertson, D.V. Mehrotra, and et al. Safety and immunogenicity of the MRKAd5 gag HIV Type 1 vaccine in a worldwide Phase 1 Study of Healthy Adults AIDS Res Hum Retroviruses 2010 10.1089/AID.2010.0151
91. G.J. Churchyard, C. Morgan, E. Adams, J. Hural, B.S. Graham, Z. Moodie, D. Grove, G. Gray, L-G. Bekker, M.J. McElrath, and et al. A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204) PLoS One 6 2011 e21225
92. L.R. Baden, S.R. Walsh, M.S. Seaman, R.P. Tucker, K.H. Krause, A. Patel, J.A. Johnson, J. Kleinjan, K.E. Yanosick, J. Perry, and et al. First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001) J Infect Dis 207 2013 240 247
93. B.M.N. Kagina, M.D. Tameris, H. Geldenhuys, M. Hatherill, B. Abel, G.D. Hussey, T.J. Scriba, H. Mahomed, J.C. Sadoff, W.A. Hanekom, and et al. The novel tuberculosis vaccine, AERAS-402, is safe in healthy infants previously vaccinated with BCG, and induces dose-dependent CD4 and CD8 T cell responses Vaccine 32 2014 5908 5917
94. S.H. Hodgson, K.J. Ewer, C.M. Bliss, N.J. Edwards, T. Rampling, N.A. Anagnostou, E. de Barra, T. Havelock, G. Bowyer, I.D. Poulton, and et al. Evaluation of the efficacy of ChAd63-MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naive individuals J Infect Dis 211 2015 1076 1086
95. M.D. Tapia, S.O. Sow, K.E. Lyke, F.C. Haidara, F. Diallo, M. Doumbia, A. Traore, F. Coulibaly, M. Kodio, U. Onwuchekwa, and et al. Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial Lancet Infect Dis 16 2016 31 42
96. G. Gao, L.H. Vandenberghe, and J.M. Wilson New recombinant serotypes of AAV vectors Curr Gene Ther 5 2005 285 297
97. E. Tobiasch, T. Burguete, P. Klein-Bauernschmitt, R. Heilbronn, and J.R. Schlehofer Discrimination between different types of human adeno-associated viruses in clinical samples by PCR J Virol Methods 71 1998 17 25
98. C-L. Chen, R.L. Jensen, B.C. Schnepp, M.J. Connell, R. Shell, T.J. Sferra, J.S. Bartlett, K.R. Clark, and P.R. Johnson Molecular characterization of adeno-associated viruses infecting children J Virol 79 2005 14781 14792
99. W. Li, A. Asokan, Z. Wu, T. Van Dyke, N. DiPrimio, J.S. Johnson, L. Govindaswamy, M. Agbandje-McKenna, S. Leichtle, D.E. Redmond, and et al. Engineering and selection of shuffled AAV genomes: a new strategy for producing targeted biological nanoparticles Mol Ther J Am Soc Gene Ther 16 2008 1252 1260
100. G-P. Gao, Y. Lu, X. Sun, J. Johnston, R. Calcedo, R. Grant, and J.M. Wilson High-level transgene expression in nonhuman primate liver with novel adeno-associated virus serotypes containing self-complementary genomes J Virol 80 2006 6192 6194
101. J. Zhu, X. Huang, and Y. Yang The TLR9-MyD88 pathway is critical for adaptive immune responses to adeno-associated virus gene therapy vectors in mice J Clin Invest 119 2009 2388 2398
102. M. Hösel, M. Broxtermann, H. Janicki, K. Esser, S. Arzberger, P. Hartmann, S. Gillen, J. Kleeff, D. Stabenow, M. Odenthal, and et al. Toll-like receptor 2-mediated innate immune response in human nonparenchymal liver cells toward adeno-associated viral vectors Hepatol Baltim Md 55 2012 287 297
103. B. Balakrishnan, D. Sen, S. Hareendran, V. Roshini, S. David, A. Srivastava, and G.R. Jayandharan Activation of the cellular unfolded protein response by recombinant adeno-associated virus vectors PLoS One 8 2013 e53845
104. M.W. Pellegrino, A.M. Nargund, N.V. Kirienko, R. Gillis, C.J. Fiorese, and C.M. Haynes Mitochondrial UPR-regulated innate immunity provides resistance to pathogen infection Nature 516 2014 414 417
105. L.E. Mays, and J.M. Wilson The complex and evolving story of T cell activation to AAV vector-encoded transgene products Mol Ther J Am Soc Gene Ther 19 2011 16 27
106. R.W. Herzog, P.A. Fields, V.R. Arruda, J.O. Brubaker, E. Armstrong, D. McClintock, D.A. Bellinger, L.B. Couto, T.C. Nichols, and K.A. High Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy Hum Gene Ther 13 2002 1281 1291
107. T. Wu, K. Töpfer, S-W. Lin, H. Li, A. Bian, X.Y. Zhou, K.A. High, and H.C.J. Ertl Self-complementary AAVs induce more potent transgene product-specific immune responses compared to a single-stranded genome Mol Ther J Am Soc Gene Ther 20 2012 572 579
108. J-C. Nault, S. Datta, S. Imbeaud, A. Franconi, M. Mallet, G. Couchy, E. Letouzé, C. Pilati, B. Verret, J-F. Blanc, and et al. Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas Nat Genet 47 2015 1187 1193
109. K.I. Berns, B.J. Byrne, T.R. Flotte, G. Gao, W.W. Hauswirth, R.W. Herzog, N. Muzyczka, T. VandenDriessche, X. Xiao, S. Zolotukhin, and et al. Adeno-associated virus Type 2 and hepatocellular carcinoma? Hum Gene Ther 26 2015 779 781
110. S. Mehendale, J. van Lunzen, N. Clumeck, J. Rockstroh, E. Vets, P.R. Johnson, P. Anklesaria, B. Barin, M. Boaz, S. Kochhar, and et al. A phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C adeno-associated virus vaccine AIDS Res Hum Retroviruses 24 2008 873 880
111. S.-W. Lin, S.E. Hensley, N. Tatsis, M.O. Lasaro, and H.C.J. Ertl Recombinant adeno-associated virus vectors induce functionally impaired transgene product-specific CD8+ T cells in mice J Clin Invest 117 2007 3958 3970
112. J. Lin, Y. Zhi, L. Mays, and J.M. Wilson Vaccines based on novel adeno-associated virus vectors elicit aberrant CD8+ T-cell responses in mice J Virol 81 2007 11840 11849
113. E. Vardas, P. Kaleebu, L-G. Bekker, A. Hoosen, E. Chomba, P.R. Johnson, P. Anklesaria, J. Birungi, B. Barin, M. Boaz, and et al. A phase 2 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 vaccine based on adeno-associated virus AIDS Res Hum Retroviruses 26 2010 933 942
114. S.M. Faust, P. Bell, B.J. Cutler, S.N. Ashley, Y. Zhu, J.E. Rabinowitz, and J.M. Wilson CpG-depleted adeno-associated virus vectors evade immune detection J Clin Invest 123 2013 2994 3001
115. C. Su, X. Duan, J. Zheng, L. Liang, F. Wang, and L. Guo IFN-α as an adjuvant for adenovirus-vectored FMDV subunit vaccine through improving the generation of T follicular helper cells PLoS One 8 2013 e66134